Immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer from parp Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
Description: Dr Constantia Pantelidou speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about a study which looked at the immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer (TNBC).nnShe reports that PARP inhibitors induce an anti-tumour immune response in BRCA1-deficient TNBC but not in BRCA1-proficient TNBC.nnDr Pantelidou explains that this T cell recruitment is mediated through activation of the STING pathway and this activation